Organogenesis accuses stockbroker of benefiting rival in share sale recommendation
This article was originally published in Clinica
Executive Summary
The artificial skin maker, Organogenesis, last week accused a Los Angeles investment banking firm of downplaying the company's stock in order to benefit its competitor, Advanced Tissue Sciences (ATS).